mRNA Vaccines & Therapeutics Market Explored by La Merie Publishing in Its New In-Demand Report Recently Uploaded at MarketPublishers.com
07 Jul 2017 • by Natalie Aster
LONDON – Historically, messenger RNA (mRNA) was recognized as a poor choice for therapeutic agent owing to its immunogenicity and relatively short half-life. However, mRNA is rather versatile and provides a number of advantages. mRNA lacks genomic integration, and its usage results in transient expression of the encoded protein; this makes mRNA particularly attractive for gene editing and vaccines. As mRNA is well defined chemically, it ensures reproducible manufacturing at high yield, activity and purity. Ongoing improvements in lipid nanoparticle formulations has considerably spurred the development of in vivo transfection strategies.
At present, nearly 16 mRNA vaccines and therapeutics are in clinical stages. Furthermore, many mRNA vaccines and therapeutics are in IND and pre-IND stages.
The new in-demand report “mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals” prepared by La Merie Publishing brings updated info on the current market scenario as well as presents access to relevant info on the existing technologies, pipelines and major deals in the field. This report highlights the most prominent players in the mRNA vaccines and therapeutics market, touches upon competitive pressures, sheds light on the regulative framework, identifies lucrative funding opportunities and describes the business environment. Moreover, this research study provides a profound analysis of the mRNA vaccines and therapeutics pipeline, reviews the main stakeholders in the field, discusses the top market trends and opportunities, and offers future projections for the mRNA vaccines and therapeutics market for the short run.
Numerous insightful research studies by this publisher are available at the La Merie Publishing page at MarketPublishers.com.